Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years

NCT03935204 is registered in ClinicalTrials.gov with Xiamen University as lead sponsor.

NCT NCT03935204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03935204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years
Lead sponsor
Xiamen University
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2019
Completion date
April 1, 2021
Enrollment
627 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, condylomata acuminata